Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study

BACKGROUND: Abiraterone acetate plus prednisolone is approved to treat patients with castration-resistant prostate cancer. This study evaluated the safety and efficacy of abiraterone acetate plus prednisolone in castration-resistant prostate cancer patients with or without previous chemotherapy in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Koroki, Yosuke, Imanaka, Keiichiro, Yasuda, Yukiko, Harada, Sayuri, Fujino, Akiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405844/
https://www.ncbi.nlm.nih.gov/pubmed/34050660
http://dx.doi.org/10.1093/jjco/hyab077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405844/
https://www.ncbi.nlm.nih.gov/pubmed/34050660
http://dx.doi.org/10.1093/jjco/hyab077

Ejemplares similares